AbbVie (XSWX:ABBV) Marketable Securities: CHF0 Mil (As of Mar. 2026)


XSWX:ABBV AbbVie Inc XSWX:ABBV
65 GF Score
Price CHF206.75
GF Value CHF167.66
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Marketable Securities?

AbbVie XSWX:ABBV 65 Marketable Securities is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:ABBV with a GF Score™ of 65/100 and a GF Value™ of CHF167.66 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. AbbVie's Marketable Securities for the quarter that ended in Mar. 2026 was CHF0 Mil.

AbbVie's annual Marketable Securities increased from Dec. 2023 (CHF2 Mil) to Dec. 2024 (CHF28 Mil) but then declined from Dec. 2024 (CHF28 Mil) to Dec. 2025 (CHF22 Mil).

AbbVie  (XSWX:ABBV) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

AbbVie Marketable Securities Related Terms

AbbVie Marketable Securities Historical Data

* Premium members only.

The historical data trend for AbbVie's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Marketable Securities Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.36 26.09 1.73 27.64 22.31

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.00 33.44 22.31 0.00
XSWX:ABBV
65GF Score
AbbVie Inc XSWX:ABBV
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of CHF0 Mil mean?
AbbVie (XSWX:ABBV) has a Marketable Securities of CHF0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on AbbVie and its competitors.
Is AbbVie's Marketable Securities too high?
AbbVie's current Marketable Securities is CHF0 Mil. Overall, AbbVie has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Marketable Securities compare to MRK and JNJ?
AbbVie's Marketable Securities of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on AbbVie and its competitors. AbbVie's current Marketable Securities is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF167.66, compared to a current price of CHF206.75 — trading 23.3% above its estimated fair value. The current Marketable Securities is CHF0 Mil. AbbVie's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current Marketable Securities is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (XSWX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of CHF206.75 is trading 23.3% above its estimated GF Value™ of CHF167.66. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for XSWX:ABBV:

  • Marketable Securities: CHF0 Mil
  • GF Value™: CHF167.66 vs. price of CHF206.75 (23.3% above fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
65GF Score

Get the complete analysis for XSWX:ABBV

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF206.75
Price
CHF167.66
GF Value